Hormone levels of female patients with SLE after anti-CD19 CAR T-cell treatment do not indicate a signal of impaired ovarian reserve

Clicks: 3
ID: 324738
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #197 of 206 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 206 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: Women with systemic lupus erythematosus (SLE) are at increased risk of infertility due to disease activity and exposure to gonadotoxic therapies. Anti‑CD19 chimeric antigen receptor (CAR) T‑cell therapy has recently been shown to induce durable, drug‑free remission in refractory SLE; however, its effects on ovarian function remain unknown. We assessed longitudinal changes in reproductive endocrine markers to evaluate the impact of CAR T‑cell therapy on ovarian reserve and hypothalamic-pituitary-ovarian (HPO) axis function. METHODS: Women with severe, treatment‑refractory SLE receiving autologous anti‑CD19 CAR T‑cell therapy (Miltenyi Biomedicine) in conjunction with standard lymphodepletion at two tertiary care centres were studied. Anti‑Müllerian hormone (AMH), estradiol (E2), progesterone, follicle‑stimulating hormone (FSH), luteinizing hormone (LH), and prolactin were measured at baseline and 12 months after therapy. Blood samples were obtained independent of menstrual cycle phase. Paired statistical analyses were performed. RESULTS: Thirteen women were included; median age at CAR T‑cell therapy was 27 years. AMH levels were stable (1.54 ng/mL [IQR 0.64-3.15] vs 2.14 ng/mL [0.63-3.26]; p = 0.886). E2 (243 pmol/L [186-346] vs 484 pmol/L [277-829]; p = 0.339) and progesterone (0.90 nmol/L [0.80-0.90] vs 1.80 nmol/L [0.90-3.40]; p = 0.054) showed substantial variability without significant longitudinal change. FSH increased modestly (6.60 IU/L [4.00-7.90] vs 7.20 IU/L [4.50-9.90]; p = 0.033) without a concomitant decline in AMH. LH (6.10 IU/L [5.10-12.90] vs 7.00 IU/L [5.00-12.90]; p = 0.946) and prolactin (10.0 µg/L [8.0-10.0] vs 8.0 µg/L [5.0-9.0]; p = 0.123) remained stable. CONCLUSION: Anti‑CD19 CAR T‑cell therapy including standard lymphodepletion showed no signal of impaired ovarian reserve, as assessed by AMH and hormone profiles. Observed hormonal changes, including FSH, should be interpreted with caution given study limitations.
Reference Key
openalex_W7202286609 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ann‐Christin Pecher, Jörg Henes, Melanie Henes, Claudia Lengerke, Wolfgang Bethge, Andreas Wirsching, Tobias Rothe, Fabian Müller, Andréas Mackensen, Georg Schett, Melanie Hagen
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag413
URL
https://doi.org/10.1093/rheumatology/keag413
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.